HRP20100473T1 - Imunostimulatorne kombinacije za profilaksu i liječenje hepatitisa c - Google Patents
Imunostimulatorne kombinacije za profilaksu i liječenje hepatitisa c Download PDFInfo
- Publication number
- HRP20100473T1 HRP20100473T1 HR20100473T HRP20100473T HRP20100473T1 HR P20100473 T1 HRP20100473 T1 HR P20100473T1 HR 20100473 T HR20100473 T HR 20100473T HR P20100473 T HRP20100473 T HR P20100473T HR P20100473 T1 HRP20100473 T1 HR P20100473T1
- Authority
- HR
- Croatia
- Prior art keywords
- combination according
- immunostimulatory combination
- immunostimulatory
- hepatitis
- treatment
- Prior art date
Links
- 230000003308 immunostimulating effect Effects 0.000 title claims abstract 21
- 238000011282 treatment Methods 0.000 title claims abstract 6
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 230000000069 prophylactic effect Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 5
- 229940123189 CD40 agonist Drugs 0.000 claims abstract 4
- 208000005176 Hepatitis C Diseases 0.000 claims abstract 4
- 238000011321 prophylaxis Methods 0.000 claims abstract 4
- 239000012634 fragment Substances 0.000 claims abstract 3
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 claims abstract 3
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims abstract 2
- 239000000556 agonist Substances 0.000 claims abstract 2
- 230000004044 response Effects 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 4
- 241000711549 Hepacivirus C Species 0.000 claims 3
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 108700012707 hepatitis C virus NS3 Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200502446 | 2005-10-07 | ||
| ES200601563A ES2334472B1 (es) | 2006-06-09 | 2006-06-09 | Combinacion inmunoestimuladora para profilaxis y tratamiento de hepatitis c. |
| PCT/ES2006/000554 WO2007042583A1 (es) | 2005-10-07 | 2006-10-05 | Combinación inmunoe s t imuladora para profilaxis y tratamiento de hepatitis c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100473T1 true HRP20100473T1 (hr) | 2010-10-31 |
Family
ID=37942331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100473T HRP20100473T1 (hr) | 2005-10-07 | 2010-08-30 | Imunostimulatorne kombinacije za profilaksu i liječenje hepatitisa c |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20100047231A1 (zh) |
| EP (1) | EP1949913B1 (zh) |
| JP (1) | JP2009511452A (zh) |
| CN (1) | CN101330928B (zh) |
| AT (1) | ATE469657T1 (zh) |
| AU (1) | AU2006301171B9 (zh) |
| BR (1) | BRPI0616978A2 (zh) |
| CA (1) | CA2625506C (zh) |
| CY (1) | CY1110744T1 (zh) |
| DE (1) | DE602006014720D1 (zh) |
| DK (1) | DK1949913T3 (zh) |
| ES (1) | ES2346570T3 (zh) |
| HR (1) | HRP20100473T1 (zh) |
| PL (1) | PL1949913T3 (zh) |
| PT (1) | PT1949913E (zh) |
| RS (1) | RS51402B (zh) |
| RU (1) | RU2431499C2 (zh) |
| SI (1) | SI1949913T1 (zh) |
| WO (1) | WO2007042583A1 (zh) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101522210B (zh) | 2006-09-18 | 2017-03-22 | 阿肯色大学评议会 | 增强免疫应答的组合物和方法 |
| NZ585776A (en) * | 2007-10-30 | 2012-07-27 | Univ Arkansas | Compositions and methods of enhancing immune responses to flagellated bacterium |
| PL2214701T3 (pl) * | 2007-11-01 | 2017-01-31 | The Board Of Trustees Of The University Of Arkansas | Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria |
| US20110268757A1 (en) | 2008-12-03 | 2011-11-03 | Institut Pasteur | Use of phenol-soluble modulins for vaccine development |
| BRPI1009458A2 (pt) * | 2009-03-10 | 2016-03-01 | Baylor Res Inst | vacinas antivirais direcionadas às células de apresentação de antígeno |
| UA110024C2 (uk) | 2010-01-21 | 2015-11-10 | Вакцинний вектор і спосіб посилення імунної відповіді | |
| KR102007132B1 (ko) | 2010-06-09 | 2019-08-05 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | 캄필로박터 감염을 감소시키기 위한 백신 및 방법 |
| NZ711019A (en) | 2013-02-14 | 2019-07-26 | Univ Arkansas | Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection |
| EP2968423A4 (en) | 2013-03-15 | 2016-11-09 | Univ Arkansas | COMPOSITIONS AND METHODS FOR INCREASING IMMUNE REACTIONS AGAINST ENTERAL PATHOGENES |
| BR112018072592A2 (pt) | 2016-05-03 | 2019-04-16 | The Board Of Trustees Of The University Of Arkansas | vetor de vacina de levedura que inclui polipeptídeos imunoestimulantes e antigênicos, e métodos de uso dos mesmos |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5049390A (en) * | 1987-09-02 | 1991-09-17 | Allergy Immuno Technologies, Inc. | Liposome containing immunotherapy agents for treating IgE mediated allergies |
| CN1325517C (zh) * | 1998-07-21 | 2007-07-11 | 展马博联合股份有限公司 | 抗丙型肝炎病毒抗体及其用途 |
| AU9215101A (en) * | 2000-08-17 | 2002-02-25 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
| US7022830B2 (en) * | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
| EP2258712A3 (en) * | 2002-03-15 | 2011-05-04 | Multicell Immunotherapeutics, Inc. | Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs |
| JP2006512391A (ja) * | 2002-12-30 | 2006-04-13 | スリーエム イノベイティブ プロパティズ カンパニー | 組み合わせ免疫賦活薬 |
-
2006
- 2006-10-05 JP JP2008534032A patent/JP2009511452A/ja active Pending
- 2006-10-05 CN CN2006800457078A patent/CN101330928B/zh not_active Expired - Fee Related
- 2006-10-05 DK DK06830863.4T patent/DK1949913T3/da active
- 2006-10-05 RU RU2008117328/15A patent/RU2431499C2/ru not_active IP Right Cessation
- 2006-10-05 AU AU2006301171A patent/AU2006301171B9/en not_active Ceased
- 2006-10-05 CA CA2625506A patent/CA2625506C/en not_active Expired - Fee Related
- 2006-10-05 PL PL06830863T patent/PL1949913T3/pl unknown
- 2006-10-05 EP EP06830863A patent/EP1949913B1/en active Active
- 2006-10-05 SI SI200630732T patent/SI1949913T1/sl unknown
- 2006-10-05 DE DE602006014720T patent/DE602006014720D1/de active Active
- 2006-10-05 ES ES06830863T patent/ES2346570T3/es active Active
- 2006-10-05 AT AT06830863T patent/ATE469657T1/de active
- 2006-10-05 US US12/083,217 patent/US20100047231A1/en not_active Abandoned
- 2006-10-05 BR BRPI0616978-3A patent/BRPI0616978A2/pt not_active IP Right Cessation
- 2006-10-05 PT PT06830863T patent/PT1949913E/pt unknown
- 2006-10-05 RS RSP-2010/0373A patent/RS51402B/en unknown
- 2006-10-05 WO PCT/ES2006/000554 patent/WO2007042583A1/es active Application Filing
-
2010
- 2010-08-19 CY CY20101100769T patent/CY1110744T1/el unknown
- 2010-08-30 HR HR20100473T patent/HRP20100473T1/hr unknown
-
2013
- 2013-09-27 US US14/039,269 patent/US20140056943A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE469657T1 (de) | 2010-06-15 |
| BRPI0616978A2 (pt) | 2011-07-05 |
| US20100047231A1 (en) | 2010-02-25 |
| SI1949913T1 (sl) | 2011-02-28 |
| JP2009511452A (ja) | 2009-03-19 |
| RU2008117328A (ru) | 2009-11-20 |
| ES2346570T3 (es) | 2010-10-18 |
| PT1949913E (pt) | 2010-08-24 |
| CA2625506C (en) | 2014-06-10 |
| EP1949913A1 (en) | 2008-07-30 |
| CN101330928B (zh) | 2012-11-14 |
| RS51402B (en) | 2011-02-28 |
| WO2007042583A1 (es) | 2007-04-19 |
| CN101330928A (zh) | 2008-12-24 |
| EP1949913B1 (en) | 2010-06-02 |
| DE602006014720D1 (de) | 2010-07-15 |
| PL1949913T3 (pl) | 2010-10-29 |
| AU2006301171B2 (en) | 2011-10-27 |
| AU2006301171B9 (en) | 2012-03-29 |
| CA2625506A1 (en) | 2007-04-19 |
| CY1110744T1 (el) | 2015-06-10 |
| RU2431499C2 (ru) | 2011-10-20 |
| DK1949913T3 (da) | 2010-10-04 |
| AU2006301171A1 (en) | 2007-04-19 |
| US20140056943A1 (en) | 2014-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100473T1 (hr) | Imunostimulatorne kombinacije za profilaksu i liječenje hepatitisa c | |
| Quan et al. | Ginseng and Salviae herbs play a role as immune activators and modulate immune responses during influenza virus infection | |
| WO2007130493A3 (en) | Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity | |
| EA200601761A1 (ru) | Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения | |
| WO2017143449A1 (en) | Smc combination therapy for the treatment of cancer | |
| NO20083793L (no) | Antistoffer mot amyloid-beta peptid | |
| BRPI0606867A2 (pt) | formulação lìquida; forma de dosagem unitária farmacêutica; kit; recipiente; método para aumentar a estabilidade de um polipeptìdeo de ligação a antìgeno numa formulação; método para preparar uma forma de dosagem unitária farmacêutica; formulação estável; formulação; e produto terapêutico | |
| DE60121136D1 (de) | Proteasom-influenzavirus-impfstoffzusammensetzung | |
| MX2009001412A (es) | Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas. | |
| EA200702656A1 (ru) | Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение | |
| JP2009511452A5 (zh) | ||
| EA200801411A1 (ru) | Новые адъюванты на основе конъюгатов и производных бис-ацилоксипропилцистеина и их применения в фармацевтических композициях | |
| MY197684A (en) | Oncolytic virus and method | |
| JP5745577B2 (ja) | Ｃｄ４０アゴニスト抗体／ｉ型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用 | |
| Ellerhoff et al. | Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus | |
| AR053899A1 (es) | Formulaciones que continen glimepirida y/o sus sales | |
| AR054259A1 (es) | Vacuna contra virus de papiloma humano (hpv) | |
| WO2006032525A3 (en) | Combinational therapy for treating cancer | |
| NO20051561L (no) | Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine. | |
| HRP20150363T1 (hr) | Kompozicije koje sadrže core-1 pozitivni mikroorganizam i njihova primjena za lijeäśenje ili profilaksu tumora | |
| MX2022004944A (es) | Composiciones y metodos para minimizar la perdida de proteinas a concentraciones de proteinas bajas. | |
| WO2006072946A3 (en) | Hsp60, hsp60 peptides and t cell vaccines for immunomodulation | |
| MX2011004176A (es) | Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo. | |
| MX2022009549A (es) | Tratamiento que implica vacunacion con antigeno y agentes de union que se unen a pd-l1 y cd137. | |
| Yang et al. | The immunogenicity of Alum+ CpG adjuvant SARS-CoV-2 inactivated vaccine in mice |